key: cord-0868741-av3ovm5e
authors: Casati, B.; Verdi, J. P.; Hempelmann, A.; Kittel, M.; Klaebisch, A. G.; Welker, S.; Asthana, S.; Boskovic, P.; Man, K. H.; Radlwimmer, B.; Stebbins, C. E.; Miethke, T.; Papavasiliou, F. N.; Pecori, R.
title: ADESSO detects SARS-CoV-2 and its variants: extensive clinical validation of an optimised CRISPR-Cas13-based COVID-19 test
date: 2021-06-22
journal: nan
DOI: 10.1101/2021.06.17.21258371
sha: 4d9e07e98ff0eadf27c49398ac435e6fea570847
doc_id: 868741
cord_uid: av3ovm5e

With the coronavirus disease 19 (COVID-19) pandemic now deep into its second year, widespread testing for the detection of the causative severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is fundamental. The gold standard reverse transcription quantitative PCR (RT-qPCR) cannot keep up with the high demand alone, therefore alternative diagnostic tests are needed. Here we present ADESSO (Accurate Detection of Evolving SARS-CoV-2 through SHERLOCK Optimisation), an optimised version of the CRISPR-based SHERLOCK (Specific High-sensitivity Enzymatic Reporter unLOCKing) assay. After an extensive validation on 983 clinical samples, we demonstrated that ADESSO has a sensitivity of 96% and a specificity of 100% on extracted RNA, comparable to RT-qPCR. Its performance on unextracted samples still allows the detection of the more infectious 75% of the COVID-19 positive population, making it suitable for point-of-care (POC) testing. Interestingly, our in parallel comparison of 390 matching swab and gargle samples showed consistently lower viral loads in gargle specimens. We also validated ADESSO for the detection of the B.1.1.7 variant and demonstrated that ADESSO is adaptable to any variant of concern in less than one week, a critical feature now that worrisome SARS-CoV-2 variants are spreading all around the world.

drop in sensitivity when gargling was used as sampling method for both ADESSO and qPCR. Finally, in less than one week we adapted ADESSO to specifically identify SARS-CoV-2 134 variants in clinical samples by modifying the primers and crRNAs used for amplification and 135

detection. The adapted ADESSO can identify the presence of a variant within one hour of 136 sample submission, thus eliminating the need for sequencing, while RT-qPCR tests would 137 require an additional day or two on top of the already slower turnaround. Considering the risk 138 posed by the spread of the new SARS-CoV-2 variants, this feature is highly relevant in the 139 current phase of the COVID-19 pandemic and in the near future 52 . 140 141 142 RESULTS

A SHERLOCK-based assay for SARS-CoV-2 detection in clinical samples 145

The need for a rapid and sensitive COVID-19 POC test has been and will remain a significant 146 factor to contain the spread of SARS-CoV-2. CRISPR Dx technologies represent a viable option 147

for the development of such a test 33 . For this reason, we first aimed to reproduce and adapt a 148

Cas13-based molecular detection platform called SHERLOCK (Specific High Sensitivity 149

Enzymatic Reporter UnLOCKing) 39 for the detection of SARS-CoV-2 in clinical samples. 150 SHERLOCK is based on two main steps: (a) isothermal amplification of viral RNA via RT-RPA 151

and (b) detection of a specific RNA sequence by Cas13 protein followed by trans-cleavage of a 152 labeled reporter, which can be detected via a lateral flow-based visual readout 39 ( Figure 1A) . 153 During the RT-RPA, RNA is retro-transcribed and amplified to dsDNA using specific primers 38 154 and a T7 promoter is added to the amplicon by including its sequence in the forward primer. 155

This feature is necessary for the Cas13 detection step, where a T7 RNA polymerase transcribes 156 the amplified dsDNA back into RNA, which can be specifically recognised by Cas13 protein in 157 complex with a crRNA complementary to the target. The specific binding between the crRNA complex and its target RNA activates Cas13 collateral activity, leading to cleavage of an 159 RNA reporter and generation of a detectable signal. Finally, the resulting signal can be read on 160 a lateral flow-based visual readout. For this readout an RNA reporter flanked by biotin and 161 fluorescein (FAM) is used in combination with anti-FAM antibodies labelled gold nanoparticles 162 used to visualise the reporter. In a negative sample, the reporter is intact and is captured by a 163 line of streptavidin resulting in a first band called "control band". In a positive sample, the 164 reporter is cut, therefore the first half of the reporter containing biotin is captured by streptavidin, 165 while the other half containing FAM is captured by a second line of antibodies resulting in the 166 appearance of the so-called "test band". The band intensity ratio between the test band and the 167 control band indicates the portion of reporter that has been cut, which reflects the level of Cas13 168 activation and thus the amount of target RNA that was detected in the sample ( Figure 1A) . 169 We first generated SARS-CoV-2-specific guide sequences, purified LwaCas13a protein 53 170 (Figure S1A ,B) and tested the system's detection sensitivity in the absence of a pre-171 amplification step using serial dilutions of an in-vitro-transcribed (IVT) fragment of the SARS-172

CoV-2 S gene. As previously published, a sensitivity of 10 8 aM was observed 39 (Figure S1C ). 173 We then assessed the sensitivity of our test when combining the Cas13 detection with an RT-174

RPA pre-amplification step on SARS-CoV-2 genes S and Orf1a, as formerly described 54 . A 2-175 fold improvement of the previously published sensitivity was obtained 54 . Indeed, we detected 176 SARS-CoV-2 gene S at a concentration of 10aM (5 cp/μl) and gene Orf1a at a concentration of 177 100aM (50 cp/μl) ( Figure 1B) . This improvement is most likely due to the replacement of 178

ProtoScript II Reverse Transcriptase (RT) with M-MuLV RT, which retains a functional RNase H 179 domain that degrades DNA:RNA hybrid intermediates and thereby improves the efficiency of 180 RT 55 (Figure S1D) . We then used the set of primers and crRNA for S to conduct a blind test on 181 30 clinical samples. These samples were NP swabs collected in saline (0.9% NaCl) and they 182

were previously tested for SARS-CoV-2 via RT-qPCR (Roche Cobas System) at the Medical 183

University Hospital Mannheim. The specimens were frozen and transported to our laboratory, 184

where we extracted RNA and performed SHERLOCK in duplicates. Additionally, the CDC 2019-185

nCoV Real-Time RT-PCR Diagnostic Panel 56 was also performed as a control. Using 186 SHERLOCK, we were able to identify all 10 positive samples ( Figure 1C , Table S1 ). Notably, 187

we detected sample 28, which had a very low viral titer (corresponding to a high Ct value). 188 These results demonstrate that SHERLOCK can be used as an alternative method to detect 189 SARS-CoV-2 in RNA extracted from clinical samples. 190 191 192 SARS-CoV-2 direct detection from clinical samples 193 RNA extraction is a time-consuming, labor-intensive and costly step for COVID-19 diagnosis 194 ( Figure 1A ) and shortage of RNA extraction kits has been a global issue throughout the 195 pandemic 57, 58 . Different studies have already demonstrated that it is possible to omit it 41,43,59,60 . 196 Therefore, after demonstrating the high potential of SHERLOCK as a diagnostic test for 19, we attempted to improve our protocol in order to avoid the RNA extraction step, thus making 198 the test faster and cheaper (Figure 2A) . First, we compared different lysis methods by treating 199 one known positive sample (sample #30 in Figure 1C and Supplementary File 1) with either 200

QuickExtract DNA Extraction solution (Lucigen, #QE09050), Luna Cell Ready Lysis Buffer 201 (NEB, #E3032) or 5% Triton X 100 (Carl Roth, #3051.3) and incubating it for 5 min at 95°C. We 202 performed the experiment in triplicates for each lysis method and we were able to successfully 203 detect SARS-CoV-2 directly after lysing the sample with QuickExtract DNA Extraction solution 204

and Luna Cell Ready Lysis Buffer ( Figure 2B ). Lysis with 5% Triton X 100 did not allow SARS-205

CoV-2 detection, although it was successfully performed in another study 59 . To improve the 206 sensitivity of our test, we first optimised the amount of RT units and sample input in the RT-RPA 207 step using dilutions of synthetic SARS-CoV-2 genome. We observed the best results with 6 U/μl 208 of RT and 2.5 μ l of sample input per reaction ( Figure S2A) . Additionally, we compared our 209 standard set of RPA primers and Cas13 crRNA for S with other sets designed to target different 210 genes of SARS-CoV-2, namely N and Orf1a. First, we assessed their performance on serial 211

dilutions of a positive sample (sample #6 in Figure 1C and Supplementary File 1) ( Figure  212 S2B). Then, we compared the sensitivity of the best two candidates, S and Orf1a, on dilutions of 213 synthetic SARS-CoV-2 genome 61 . The set of RPA primers and Cas13 crRNA for S remained the 214 most sensitive one ( Figure S2C ). We therefore selected it for all the following experiments. In 215 order to assess the sensitivity of our test on unextracted samples, we spiked in serial dilutions of 216 SARS-CoV-2 synthetic genome in a negative sample lysed with QuickExtract solution and we 217

performed SHERLOCK on the S gene. We were able to consistently detect 10 cp/μl ( Figure  218 2C). We then proceeded with the evaluation of the diagnostic potential of SHERLOCK on 219 unextracted samples (so-called direct SHERLOCK) by performing a second blind test on 160 220 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 22, 2021. ; clinical samples. Positive samples were considered those which resulted in a band intensity 221 ratio (test band/control band) higher than 0.2. This threshold was defined based on the band 222 intensity ratio obtained in all the negative controls used in this study and the negative samples 223 analysed in Figures 2 and 4 (n = 282 + 467; Figure S3A ). Direct SHERLOCK was able to 224 identify 73 out of 93 positive samples resulting in a sensitivity of 78% ( Figure 2D ,E and Table  225 S1). Importantly, despite an apparent LoD equivalent to Ct 27, samples with lower Ct values 226

and high viral loads resulted in a highly variable band intensity ratio with some being very close 227 to the 0.2 threshold ( Figure 2D) . For this reason, we decided to proceed with a step-by-step 228 optimisation of the direct SHERLOCK protocol. 229 230 231

ADESSO: an optimised and highly sensitive SHERLOCK assay 232

Considering the results of the detection of SARS-CoV-2 directly from clinical samples ( Figure  233 2), we aimed at optimising the SHERLOCK protocol to develop a direct SARS-CoV-2 diagnostic 234

test that is as sensitive as possible. Therefore, we evaluated alternative reagents and different 235 reaction conditions for each one of the three main steps in SHERLOCK, namely, 1) sample 236 lysis, 2) RT-RPA and 3) Cas13 detection (Figure S4A ), to increase both sensitivity and speed 237 of the test. At this stage, we assessed Cas13 activation also via a fluorometer to monitor the 238 speed of the reaction in real time. The fluorescence readout is based on the use of an RNA 239

reporter flanked by a fluorophore and a quencher. Upon Cas13-mediated cleavage of the  240 reporter, the fluorophore is cut from the quencher and its fluorescent signal can be detected by 241 a fluorometer ( Figure S4A) . First, we measured the RNAse activity in a swab sample collected 242 in saline and lysed with the method selected in Figure 2 (QuickExtract DNA Extraction solution 243

and incubation at 95°C for 5 min). To evaluate RNAse activity, RNaseAlert was added to the 244 sample following lysis and fluorescence was measured to evaluate the corresponding nuclease 245 activity. Notably, addition of RNase inhibitors in the lysis buffer prior to heating was sufficient to 246

inhibit RNAse activity almost completely ( Figure 3A) Remarkably, while the false negative sample is still negative with 1xRPA, it results positive for 257 final concentrations of RPA from 2x to 5x, with a decrease in band intensity ratio when using the 258 4xRPA and 5xRPA concentrations (Figure 3C, S4B) . Considering this and bearing in mind the 259 cost per single test, we decided to proceed using a 2xRPA concentration. To further confirm this 260 improvement, we compared 1xRPA and 2xRPA on 5 samples with Ct values close to the LoD 261 determined in Figure 2 (samples #L95, L96, L111, L122 and L123, Supplementary File 1). We 262 observed an improvement in the 2xRPA reactions with these samples as well (Figure 3D, S4C) . 263 Furthermore, in order to optimise the Cas13 detection step we made a ten-fold dilution of a 264 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 22, 2021. ; positive RT-RPA reaction (50 cp/μl) and we performed Cas13 detection using the original 265 concentration of Cas13/crRNA (45/22.5 nM) 39,53,54 , in comparison to higher amounts ( Figure  266 S4D, upper panel). A concentration of Cas13/crRNA of 90 nM each leads to an improved  267  reaction, reaching the plateau after 15 min only, compared to 30 min for the other two  268 concentrations ( Figure 3E, S4D , lower panel). We also confirmed that a 10-min incubation for 269

Cas13 detection performed in half the volume is sufficient to yield a clearly positive outcome in 270 the lateral flow detection assay ( Figure 3F, S4E) , which is an essential aspect for a POC test. 271

Moreover, a shorter Cas13 reaction allows us to extend the incubation time of the RT-RPA step 272

for highly sensitive reactions 53 without affecting the total time of the assay. Finally, we assessed 273 the sensitivity of this optimised protocol on serial dilutions of SARS-CoV-2 synthetic genome 274

and we observed a robustly reproducible sensitivity of 2.5 cp/μl ( Figure 3G ). We named this 275 new optimised diagnostic assay ADESSO (Accurate Detection of Evolving SARS-CoV-2 276 through SHERLOCK Optimisation) ( Figure 3H ).

Evaluation of ADESSO performance on clinical samples in direct comparison to RT-280 qPCR. 281 We used ADESSO to test a total of 195 clinical samples in direct comparison to the RT-qPCR 282 protocol routinely used in the clinics. To allow a fair comparison between the methods, we first 283 selected 95 positive and 100 negative individuals (via COBAS RT-qPCR on NP swab). For each 284 of these specimens, RNA was re-extracted and analysed by RT-qPCR (Tib Molbiol) and 285

ADESSO. Additionally, ADESSO was also performed directly on unextracted samples. Finally, 286

we also obtained gargled saline from the same individuals as an alternative sampling method, 287 which would be ideal for POC testing. Those samples were treated exactly as the NP swabs 288 ( Figure 4A) . Importantly, the ADESSO results were analysed without knowing the outcome of 289 the COBAS RT-qPCR used as the reference. 290

The results of this experiment are summarised in Table 1 . ADESSO on RNA extracted from 291 swabs was able to correctly identify most positive samples (91 out of 95), resulting in a 292 sensitivity of 96% ( Figure 4B) . Interestingly, all the false negative samples have Ct values 293 higher than 31, corresponding to lower viral loads (<100cp/μl) and therefore a lower probability 294 of spreading the virus 11,51 . RT-qPCR (Tib Molbiol) performed on the same samples was largely 295

in agreement with the COBAS RT-qPCR, with highly correlated Ct values ( Figure 4F ). 296

However, using this method we were able to identify 89 out of 95 positive samples resulting in a 297 sensitivity of 94% (Table 1 and Figure 4F ). As expected, ADESSO on unextracted samples 298 resulted in a lower sensitivity (77%), with all false negative samples having Ct values higher 299 than 29 (~100cp/μl) ( Table 1 and Figure 4C ). The same analysis was performed on gargle 300 saline samples. In this case, ADESSO on extracted RNA correctly identified 74 out of 95 301 positive samples resulting in a sensitivity of 78%, with most false negative samples having Ct 302 values higher than 30 and few with Ct values between 28 and 29 ( Figure 4D) . Interestingly, this 303 drop in sensitivity does not seem to be related to the detection method but rather to the 304 sampling method. Indeed, the same decrease in sensitivity (to 79%) was observed also for RT-305 qPCR (TibMolBio), with true positive samples resulting in higher Ct values (Table 1 and Figure  306 4G). Finally, as observed for swabs, ADESSO on unextracted gargle saline samples resulted in 307 a lower sensitivity (65%) ( Figure 4E and Table 1 ). In this latter case, false negative samples 308 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 22, 2021.

have different Ct values, with some corresponding to high viral loads in swabs (analysed by 309 COBAS RT-qPCR) (dark red dots in Figure 4E and 4H). The overall decrease in sensitivity is in 310 agreement with the consistently higher Ct values observed in gargle specimens compared to 311 their matched swab samples analysed via Tib Molbiol RT-qPCR ( Figure 4H ). 312

Altogether, these results validate the high potential of ADESSO as a POC test for the detection 313 of SARS-CoV-2 infected individuals. Notably, ADESSO on extracted RNA, either from swab or 314 gargle samples, performed as well as RT-qPCR (Tib Molbiol) in terms of sensitivity and 315 specificity. Additionally, our data also shows an important difference in the detection of SARS-316

CoV-2 when gargling with saline was used as a sampling method. Even though this approach 317 would be better suited to a POC test, we observed a clear reduction in sensitivity, independently 318 of the detection method used. 319 320

Adaptation of ADESSO for detection of SARS-CoV-2 variants: a flexible and powerful 321 assay to rapidly identify specific variants or mutations. 322

Since the beginning of the pandemic, SARS-CoV-2 has evolved considerably. The first variants 323

to appear carried a D614G mutation in the spike protein 62 , which is now dominant and shared 324 between all the existing variants. While several variants exist, here we focus our attention on 325 two variants of concern: SARS-CoV-2 B. ( Figure 5A ). Finally, there is growing evidence that these new variants could impair the efficacy 337 of current monoclonal antibody therapies and vaccines because of the several mutations 338 located in the spike gene 67-69 . For this reason, it is now essential to quickly identify individuals 339 infected by SARS-CoV-2 variants. The UK variant is the major concern in Europe and Germany, 340 therefore we adapted our test to detect the deletion (ΔHV69-70) specific to this strain. We called 341 this adapted test ADESSO-UK ( Figure 5A,B) . First, we designed two different crRNAs able to 342 recognise either the original Wuhan strain or the UK variant, called respectively crRNA HV69-70 343 and crRNA Δ HV69-70 ( Figure 5B ). Then we optimised RT-RPA primers to amplify the region of 344 SARS-CoV-2 genome containing HV69-70 and we selected the more sensitive set 1 for further 345 analysis ( Figure S5A ). Finally, we performed a blind test on positive clinical samples carrying 346 either UK or SA variants. We first applied ADESSO for the detection of SARS-CoV-2 and we 347

were able to detect all positive samples but one (sample #11, Figure 5C ). Then, using 348 ADESSO-UK (crRNA Δ HV69-70 or HV69-70) we were able to correctly identify all the samples 349

carrying the UK variant and we could distinguish the ones bearing the SA strain (samples #1-13, 350 Figure 5D ,E and S5B). Interestingly, among the three samples carrying the SA variant, only 351 sample #11 was not detected via ADESSO. Sequencing analysis of the viral genome in these 352 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 22, 2021. ; https://doi.org/10.1101/2021.06.17.21258371 doi: medRxiv preprint three samples showed that they all shared the deletion Δ 242-244, but only sample #11 carried 353 the R246I mutation ( Figure S5C ). This mutation falls exactly within the bases recognised by the 354 3' end of the forward primer used in the RT-RPA step of ADESSO, thus disrupting its function 355 ( Figure 5F ). Notably, the assay seems to be resistant to deletions of several nucleotides 356 occurring in sequences that are complementary to the central region of the primer ( Figure 5F ). 357

Altogether, these results show how ADESSO can be readily adapted for the detection of SARS-358

CoV-2 variants of concern and even specific mutations. The entire adaptation of the test took 359 less than one week, from the selection of a unique mutation for the UK variant to the validation 360 of the adapted protocol, including designing and production of the specific reagents. This 361 feature of our assay is a crucial aspect in the current phase of the COVID-19 pandemic, where 362 quick and sequencing-independent detection of variants is essential to contain their spread 52 has a sensitivity of 96% on RNA extracted from swabs and a sensitivity of 77% when performed 382 directly on unextracted swab samples. This drop in sensitivity is due to a decreased LoD at Ct 383 29, corresponding to low viral titers and minimal infectiousness 11,51 . However, skipping the RNA 384 extraction step considerably reduces the sample-to-result turnaround time and allows more 385 frequent testing, which is suggested to be essential for efficient identification of viral infections 386 and isolation of carriers to contain the pandemic 30 . Other advantages are the lower need for 387 RNA extraction kits, whose shortage has been a global issue throughout the pandemic 57,58 , and 388 the higher test portability, which makes ADESSO appropriate for POC testing. To further 389

increase the POC suitability of ADESSO, we assessed its performance in comparison with RT-390 qPCR on gargle samples obtained from the same individuals from whom swabs were collected. 391

Interestingly, we observed a loss in sensitivity independently of the diagnostic test. On RNA 392 extracted from gargle samples, ADESSO showed a sensitivity of 78%, comparable with a 79% 393 sensitivity of the RT-qPCR.

In line with what we observed for swab samples, the sensitivity of 394 ADESSO decreased to 65% when performed directly on unextracted gargle samples ( Table 1) . 395 This overall loss of sensitivity can be attributed to the sampling method, which leads to a 396 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 22, 2021. general increase in Ct values in gargle samples compared to swabs collected from the same 397 individuals at the same time ( Figure 4H ). To alternative methods should be considered and evaluated in comparison to gargling and NP 405

swabbing, for example self-collection of nasal swabs, whose feasibility and reliability are already 406 being investigated 72 . 407

Importantly, the cohort of positive individuals analysed in our study was selected randomly and 408 displays a normal distribution of Ct values, covering the full range of viral titers between Ct 17 409

and Ct 38 (Figure S6A,B) suggesting that immediate and widespread application of ADESSO would be of great help to 419 contain the pandemic. In particular, by applying ADESSO on swab samples without RNA 420 extraction, an estimated ~75% of the infected population would be successfully detected, while 421 ~25% of the infected individuals could be missed (Figure 4 and S6A) . Importantly, this 25% 422 portion corresponds to individuals with Ct values higher than 29, associated with low viral titers 423

and here, is necessary to determine the real LoD of a diagnostic test. This is crucial to allow a fair 430 comparison between sensitivities resulting from independent studies, which can be greatly 431

influenced by the choice of the tested population. 432

The importance of testing is further highlighted by the recent emergence of SARS-CoV-2 433 variants, which poses a new threat for humanity, as India's recent tragic crisis has shown 52,74 . 434

This is of utmost criticality because mutations in the viral genome might impair both molecular 435 and antigen-based tests, thus leading to false negative results. In these situations, being able to 436

promptly adapt a test is fundamental and ADESSO offers such an advantage. Here, in less than 437 a week we adapted the test for the detection of the B.1.1.7 variant. Based on the publicly 438 available SARS-CoV-2 sequences (https://www.gisaid.org), ADESSO can be adapted to any 439 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 22, 2021. ; variant of concern, thus providing an all-in-one SARS-CoV-2 detection and variant identification 440 tool without need for sequencing. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) μ l of benzoase to lysis buffer (20 mM Tris pH 8.0, 500 mM NaCl, 1 mM 481 DTT)) and lysed by sonication. Lysate was cleared by centrifugation at 10 k rpm for 1h at 4°C. 482

Supernatant was purified using a 1 ml HIS-Trap column (Cytiva) slurry and affinity 483 chromatography was performed using the ÄKTA pure system with lysis buffer for washing steps 484

and an imidazole gradient for elution. After initial purification, the protein sample was incubated 485

with SUMO protease (ThermoScientific) as per the manufacturer's instructions at 4°C overnight 486

to remove the affinity tags. The sample was then re-applied to a 1 ml HIS-Trap column. Both the 487 SUMO protease (which itself has a 6xHIS tag) and the cleaved affinity tag bind to the resin, 488

while pure Cas13 eluted in the wash step. A final size-exclusion chromatography step was 489 performed using the ÄKTA pure system using 10 mM HEPES pH 7.0, 5 For the first blind test (Figure 1) , RNA was extracted from the clinical samples with the 530

QIAamp® Viral RNA Mini kit (Qiagen, #52904) following the manufacturer's instructions (140μl 531 of swab were extracted and eluted in 60μl). For the validation study (Figure 4) For the validation study (Figure 4) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 22, 2021. ; https://doi.org/10.1101/2021.06.17.21258371 doi: medRxiv preprint (Lucigen, #QE09050). In the optimised protocol (Figure 4) produce the crRNAs in our lab we followed a previously published protocol 53 . In short, the 569 templates for the crRNAs were ordered as DNA oligonucleotides from Sigma-Aldrich with an 570 appended T7 promoter sequence. These oligos were annealed with a T7-3G oligonucleotide, 571

and amplified product was then added to the mix and, after vortexing and spinning down, the mixture 600 was incubated for 10 minutes at 37°C in a heat block. The Cas13 protocol was optimised 601 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 22, 2021. as intensity ratio (test band/control band) and test were considered positive for value of intensity 613 ratio above 0.2 based on the results shown in Figure S3 . File 1) . A true negative sample (#L126, 882

Supplementary File 1) is used as negative control. The lateral flow strips whose band intensity 883 ratios are plotted here are shown in Figure S4B . 1xRPA corresponds to the standard amount of 884 RPA described in the original SHERLOCK protocol 53 and 5xRPA corresponds to the optimal 885 amount recommended by the manufacturer. D. Confirmation of the improved SHERLOCK 886 sensitivity with 2xRPA compared to 1xRPA on clinical samples with Ct values close to our LoD 887 based on Figure 2 (Supplementary File 1) . The lateral flow strips whose band intensity ratios 888

are plotted here are shown in Figure S4C . E. Optimisation of the Cas13 reaction kinetics by 889

increasing the amount of Cas13 protein and crRNA in the reaction with fluorescence readout. 890

The reaction kinetics is evaluated by measuring the fluorescence signal at different time-points. 891

The complete 3-hour analysis is shown in Figure S4D . removed from the sample by re-applying the sample to the nickel column, leaving >98% pure 967 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 22, 2021. ; https://doi.org/10.1101/2021.06.17.21258371 doi: medRxiv preprint

Incubation period of 2019 novel coronavirus 684 (2019-nCoV) infections among travellers from

The Incubation Period of Coronavirus Disease

Publicly Reported Confirmed Cases: Estimation and Application

Virological assessment of hospitalized patients with COVID-2019

Temporal profiles of viral load in posterior oropharyngeal saliva samples 692 and serum antibody responses during infection by SARS-CoV-2: an observational cohort 693 study

Epidemiological Correlates of Polymerase Chain Reaction Cycle 695

Threshold Values in the Detection of Severe Acute Respiratory Syndrome Coronavirus 2 696 (SARS-CoV-2)

Duration of infectiousness and correlation with RT-PCR cycle 698 threshold values in cases of COVID-19

Quantifying SARS-CoV-2 transmission suggests epidemic control with 701 digital contact tracing

Suppression of a SARS-CoV-2 outbreak in the Italian municipality of 703

Spread of SARS-CoV-2 in the Icelandic Population

Presumed Asymptomatic Carrier Transmission of COVID-19

Transmission of 2019-nCoV Infection from an Asymptomatic Contact in 708

UK: a national, population-based, modelling study

Effects of COVID-19 on business and research

Test sensitivity is secondary to frequency and turnaround time for 740 COVID-19 screening

Analytical sensitivity and efficiency comparisons of SARS-CoV-2

RT-qPCR primer-probe sets

Rapid, point-of-care antigen and molecular-based tests for diagnosis of 744

SARS-CoV-2 infection

C2c2 is a single-component programmable RNA-guided RNA-749 targeting CRISPR effector

N 1-Methyladenosine detection with CRISPR-Cas13a/C2c2

Targeting by Functionally Orthogonal Type VI-A CRISPR-Cas Enzymes

Loop-mediated isothermal amplification of DNA

Nucleic acid detection with CRISPR-Cas13a/C2c2

Multiplexed and portable nucleic acid detection platform with 762

Point-of-care testing for COVID-19 using SHERLOCK diagnostics

CRISPR-Cas12-based detection of SARS-CoV-2. Nat

Streamlined inactivation, amplification, and Cas13-based detection 769 of SARS-CoV-2

Rapid, Sensitive, and Specific Severe Acute Respiratory Syndrome 771

Coronavirus 2 Detection: A Multicenter Comparison Between Standard Quantitative Reverse-772

Transcriptase Polymerase Chain Reaction and CRISPR-Based DETECTR

Ultra-sensitive and high-throughput CRISPR-p owered COVID-19 775 diagnosis

Clinical validation of a Cas13-based assay for the detection of 777 SARS-CoV-2 RNA

Easy-to-Deploy Protocol for Cas13-Based Detection of 779

SARS-CoV-2 Genetic Material

Amplification-free detection of SARS-CoV-2 with CRISPR-Cas13a and 781 mobile phone microscopy

Letter of Authorization for SARS-CoV-2 RNA DETECTR Assay

Predicting Infectious Severe Acute Respiratory Syndrome Coronavirus

From Diagnostic Samples

India's COVID crisis flags need to forecast variants

SHERLOCK: nucleic acid detection with CRISPR nucleases

A protocol for detection of COVID-19 791 using CRISPR diagnostics

An enhanced isothermal amplification assay for viral detection

CDC 2019-nCoV Real-Time RT-PCR Diagnostic Panel Instructions for Use

An alternative workflow for molecular detection 797 of SARS-CoV-2 -escape from the NA extraction kit-shortage

RNA Extraction Kits for COVID-19 Tests Are in Short Supply in US

Massive and rapid COVID-19 testing is feasible by extraction-free 803

SARS-CoV-2 RT-PCR

genome by using alternative sets of primers-crRNA targeting N2 (version 1 and version 2), 985Orf1a 61 and S genes on dilutions of a COVID-19 positive sample (sample #6 in Figure 1C ). C. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted June 22, 2021. ; https://doi.org/10.1101/2021.06.17.21258371 doi: medRxiv preprint